Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

SELL
$314.42 - $351.91 $414,405 - $463,817
-1,318 Reduced 63.79%
748 $263,000
Q1 2023

May 18, 2023

BUY
$283.23 - $323.1 $200,526 - $228,754
708 Added 52.14%
2,066 $651,000
Q4 2022

Feb 16, 2023

SELL
$285.76 - $321.48 $203,461 - $228,893
-712 Reduced 34.4%
1,358 $392,000
Q3 2022

Nov 16, 2022

BUY
$273.83 - $305.53 $99,674 - $111,212
364 Added 21.34%
2,070 $599,000
Q2 2022

Nov 15, 2022

BUY
$234.96 - $292.55 $88,344 - $109,998
376 Added 28.27%
1,706 $481,000
Q1 2022

May 17, 2022

SELL
$221.42 - $260.97 $3.3 Million - $3.89 Million
-14,920 Reduced 91.82%
1,330 $347,000
Q4 2021

Feb 18, 2022

BUY
$177.01 - $223.45 $2.88 Million - $3.63 Million
16,250 New
16,250 $269,000
Q1 2021

May 18, 2021

SELL
$207.02 - $241.31 $269,747 - $314,426
-1,303 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$207.01 - $276.09 $269,734 - $359,745
1,303 New
1,303 $308,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Sky View Investment Advisors, LLC Portfolio

Follow Sky View Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sky View Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sky View Investment Advisors, LLC with notifications on news.